Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMY109 in women with endometriosis
2023-507289-14-00Phase 2Authorised
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing AMY109 with Placebo (2 arms). Primary endpoints: Change in revised American Society of Reproductive Medicine score and Change in endometriotic nodule size on MRI. Planned start Oct 2024; status: authorised.
02
Drugs
anti-IL-8 monoclonal antibody
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2023-507289-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507289-14-00.